PROVIDENCE MICROBIOME RESEARCH CENTER PRIVATE LIMITED is technically a business entity but runs a mission oriented toward autism prevention. We are conducting a series of clinical trials that will develop an antenatal program which will reduce autism incidence in future. Our first ICMR approved the study, " fecal microbiota transfer therapy for autism" - clinical trial number: CTRI/2022/02/040457 is focused on exploring the pathophysiology of autism and developing a serum marker and treatment modality for autism. Our future projects are oriented towards exploring the uterine environment during pregnancy to discover the factors causing autism. At the end of all these studies, we will develop an antenatal program to detox pregnant women to provide a toxin-free environment for developing fetuses that will prevent autism.

Research and development

Source: Ministry of Corporate Affairs company master (open data). Capital figures are as-of the 2021 registry snapshot, not live.